Literature DB >> 1359742

Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases.

N Selve1.   

Abstract

An enteritis, based on a delayed-type hypersensitivity reaction, was induced in TNBS (2,4,4-trinitrobenzenesulfonic acid) sensitized rats by intrajejunal challenge with TNBS. This treatment induced a chronic inflammation of the distal small intestine, characterized by gross hyperaemia and oedema, as assessed by a macroscopic score. Histologically, the inflammatory response included cell infiltration by lymphocytes and histiocytes, a transmural granulomatous inflammation with multinucleated cells and activated mesenteric lymph nodes. Drug treatment with sulfasalazine or 5-aminosalicylic acid improved enteritis score. The applicability and relevance of this new model is discussed in relation to drug development and basic research of inflammatory bowel diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359742

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  4 in total

1.  Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis.

Authors:  R Newman; N Cuan; T Hampartzoumian; S J Connor; A R Lloyd; M C Grimm
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

2.  Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis.

Authors:  F Massa; A Sibaev; G Marsicano; H Blaudzun; M Storr; B Lutz
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

3.  The endogenous cannabinoid system protects against colonic inflammation.

Authors:  Federico Massa; Giovanni Marsicano; Heike Hermann; Astrid Cannich; Krisztina Monory; Benjamin F Cravatt; Gian-Luca Ferri; Andrei Sibaev; Martin Storr; Beat Lutz
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies.

Authors:  P Desreumaux; L Dubuquoy; S Nutten; M Peuchmaur; W Englaro; K Schoonjans; B Derijard; B Desvergne; W Wahli; P Chambon; M D Leibowitz; J F Colombel; J Auwerx
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.